enGene Therapeutics Inc. (ENGN): R&D Expense
$94.48M
Year ended 2025-10-31
$96.26M
Trailing 12 months to 2026-07-31
+82.8%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-10-31 | $94.48M | +146.6% | 2025-12-22, From 2024-11-01 |
| 2024-10-31 | $38.31M | +132.8% | 2025-12-22, From 2023-11-01 |
| 2023-10-31 | $16.46M | +6.4% | 2024-12-19, From 2022-11-01 |
| 2022-10-31 | $15.47M | n/a | 2024-01-29, From 2021-11-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $94.48M | +146.6% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $94.43M | -13.5% |
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $55.97M | +32.2% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $95.67M | -10.8% |
| Agenus Inc (AGEN) | 2025-12-31 | $79.34M | -49.0% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $114.15M | +6.3% |
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | $140.32M | +45.5% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $116.68M | +30.6% |
| Protara Therapeutics, Inc. (TARA) | 2025-12-31 | $42.63M | +34.5% |
Compare ENGN, MGX, CMPX, IPSC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗